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Pulmonary oxalosis in pulmonary aspergillosis syndrome
Abstract
The presence of pulmonary oxalosis in bronchoalveolar lavage (BAL) or biopsied tissue samples is considered pathognomonic for 
Aspergillus disease etiology. The finding of calcium oxalate crystals in the tissue samples infected with aspergillosis can serve 
as a vital diagnostic clue. Detection of calcium oxalate crystals is achievable within 24 hours by most hospital microbiology 
laboratories. It is much quicker than the time it takes to receive results of other tests like histopathology, sputum cultures, and 
aspergillus antigen assays. We present this case to emphasize the importance of pulmonary oxalosis as a crucial early diagnostic 
factor in pulmonary aspergillosis syndromes.
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Introduction
Aspergillus genus comprises hundreds of species 
that are ubiquitously found in soil, water, or decaying 
vegetation. A. fumigatus and A. niger comprise the 
majority of disease-causing agents in pulmonary 
aspergillosis syndromes. These include invasive 
pulmonary aspergillosis (IPA), chronic necrotizing 
aspergillosis (CNA), allergic bronchopulmonary 
aspergillosis (ABPA), and aspergilloma.
A frequently overlooked diagnostic clue for 
tissue infection by aspergillosis is the finding of 
calcium oxalate crystals. The presence of pulmo-
nary oxalosis in BAL or biopsied tissue samples 
is pathognomonic for Aspergillus disease etiology. 
Oxalic acid is a byproduct of Aspergillus metabo-
lism, which combines with calcium in the blood 
supply of invaded tissue to form calcium oxalate 
crystals. The presence of calcium oxalate crystals 
is detectable under polarized light within 24 hours 
by most hospital microbiology laboratories, 
which is earlier than the time to receive results 
of histopathology, sputum cultures, and sputum 
and blood aspergillus antigen assays. This article 
suggests that evaluation for pulmonary oxalosis 
may be included in the workup of cases suspi-
cious for aspergillosis.
Case report
A 56-year-old African-American male presen-
ted with two months’ history of weight loss, cough 
with yellowish expectorate. He also complained 
of pleuritic right-sided chest pain for one week, 
and hemoptysis for two days before admission. 
A review of systems was positive for fever and 
chills. He smoked one pack/day for 35 years, and 
had a long-standing history of alcoholism.  
At admission, he was tachycardic at 118 bpm, 
and his respiratory rate was 20 bpm. His blood 
pressure was 137/88, his temperature was 98.6°F, 
and SaO2 was 96% at room air. Other pertinent 
physical exam findings were cachexia, and in-
spiratory crackles and diminished breath sounds 
at right upper lung fields. He was admitted for 
further testing.
His complete blood count showed leukocy-
tosis at 37.5 K/μL and normocytic anemia with a 
hemoglobin of 10 mg/dL. A chest X-ray (Figure 
1A) revealed right upper lobe infiltrates. He was 
started on ceftriaxone and azithromycin for the 
treatment of community-acquired pneumonia.  
On day three, his symptoms persisted, which 
prompted broadening of antibiotics coverage 
to imipenem/cilastin 500 mg Q6 hours and tri-
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methoprim/sulfamethoxazole 800 mg/160 mg 
2 tablets BID. A repeat chest X-ray (Figure 1B) 
revealed worsening infiltrates of the right upper 
and middle lobes. His leukocytosis persisted at 
37 K/μL. AFB of a sputum sample collected at 
admission returned negative. He continued to be 
normothermic and was saturating well on room 
air. On day 4, the patient continued to have leuko-
cytosis at 32.5 K/μL. His chest X-ray (Figure 1C) 
showed worsening infiltrates. Linezolid 600 mg 
oral BID was also added to the aforementioned 
antibiotics. A CT of the chest with contrast (Fi-
gure 2) was obtained, which showed the right 
lung pulmonary consolidation with pleural ef-
fusion. His sputum culture results grew Candida 
albicans and Aspergillus niger. He was started 
on voriconazole loading dose of 6 mg/kg IV Q24 
hours (which was subsequently followed by 
4 mg/kg Q24 h). 
On day 8, his leukocytosis worsened to 62 
K/μL. Antibiotics were switched to meropenem 
1000 mg Q12 hours, azithromycin 250 mg IV 
Figure 1. Chest X-ray results showing progression of RUL infiltrates to bilateral lungs from day 1 (A), 3 (B), 4 (C), and 8 (D) of admission respectively
Figure 2. Computed tomography chest with contrast on day 4 of 
admission, showing right lung infiltrates, and right pleural effusion
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Figure 3. Showing calcium oxalate crystals in pulmonary tissue biopsy
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Q12 hours, vancomycin 750 mg Q24 hours. He 
was also started on caspofungin 70 mg IV Q24 
hours (followed by 50 mg daily on subsequent 
days). Based on the clinical course, broadened 
differential diagnoses were considered. These 
included pulmonary tuberculosis and nontuber-
culosis mycobacterial lung disease, pulmonary 
mycosis  (chronic pulmonary aspergillosis or 
histoplasmosis), cryptogenic organizing pneumo-
nia, pulmonary vasculitis (such as granulomatosis 
with polyangiitis, microscopic polyangiitis or 
eosinophilic granulomatosis with polyangii-
tis), Pneumocystis carinii (PCP) pneumonia and 
lung cancer. He had also developed respiratory 
failure requiring BiPAP. He was subsequently 
intubated and underwent bronchoscopy with 
bronchoalveolar lavage (BAL). Within 24 hours 
of collection, his BAL sample showed calcium 
oxalate crystals under polarized light. Histopa-
thology of biopsied tissue sample was negative 
for malignancy, fungal bodies, but also confirmed 
calcium oxalate crystals (Figure 3). 
His sputum sample was also tested for AFB 
stain, TB culture, mycobacterium tuberculosis 
DNA by PCR, cytology, and PCP antigen, which 
were all negative. Urine histoplasma antigen and 
pANCA and cANCA blood titers were also nega-
tive. One week later, the patient’s BAL sputum 
galactomannan antigen and Aspergillus DNA 
PCR returned positive. The serum galactomannan 
antigen was also positive. The patient’s health 
continued to deteriorate; he developed multiorgan 
system failure and died one week later. Autopsy 
was not performed and necrotizing pneumonia 
was identified as the cause of death.
Discussion
Pulmonary oxalosis is pathognomonic 
for  Aspergillus fumigatus  and  Aspergillus ni­
ger tissue invasion. Oxalic acid is a byproduct of 
Aspergillus spp. metabolism which combines with 
calcium in the blood supply of invaded tissue to 
form calcium oxalate crystals. The deposition of 
calcium oxalate crystals and Aspergillus invasion 
both contribute to further inflammation and 
tissue destruction. Calcium oxalate crystals can 
occur in all spectrum of pulmonary aspergillosis 
such as aspergilloma, allergic bronchopulmonary 
aspergillosis, chronic necrotizing aspergillosis, 
and invasive pulmonary aspergillosis (IPA), but 
is more common in the latter two which are re-
presentatives of more invasive disease. Calcium 
oxalate crystals are readily identifiable under po-
larized light microscopy as birefringent granules 
in sputum and tissue samples of the infected host. 
This result is available at most standard hospital 
laboratories within 24 hours of sample collection, 
and in the appropriate clinical situation, it can 
facilitate early initiation of antifungal treatment, 
long before the results of other tests for pulmo-
nary aspergillosis return.
Pulmonary aspergillosis is most frequently 
caused by A.  fumigatus, and less commonly by 
A. niger. Invasive pulmonary aspergillosis (IPA) 
is an acute disease that manifests clinically in 
patients with risk factors which include neu-
tropenia, prolonged use of high dose steroids, 
critical illness, and immunosuppression asso-
ciated with organ transplant, chemotherapy or 
AIDS [1]. Typical symptoms reported are similar 
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to bronchopneumonia, i.e. cough with expecto-
rating, dyspnea, fever, pleurisy, and hemoptysis. 
In contrast, CNA is a more indolent, sub-invasive 
disease in which full symptoms may take weeks 
to months from onset of Aspergillus exposure to 
become fully evident. CNA experience symptoms 
similar to IPA, with the addition of weight loss. 
Risk factors for CNA are centered around mild 
levels of immunosuppression, which include be-
ing elderly, underlying chronic lung diseases such 
as COPD, history of radiation therapy, diabetes 
mellitus, alcoholism, chronic liver disease, and 
low-dose corticosteroid therapy [1–3]. Patients 
with COPD are known to have pulmonary paren-
chymal modifications, which increases their risk of 
infections. Alcoholism is also known to affect in-
nate and adaptive pulmonary immunity resulting 
in subclinical immunosuppression that becomes 
apparent with a heavy burden of infection [3, 4]. 
Our patient’s indolent prehospital course was con-
sistent with CNA secondary to chronic alcoholism 
and COPD, and his disease progressed rapidly to 
IPA and became critically ill after he was admitted.
The man was diagnosed with IPA based 
on positive respiratory cultures for Aspergillus, 
bronchial necrosis during bronchoscopy, ima-
ging findings, and positive sputum culture, and 
galactomannan antigen assay which was positi-
ve in both sputum and blood (which returned 
two weeks later). Histopathology with Grocott’s 
methenamine silver stain of the tissue sample 
from his right upper lobe biopsy was negative for 
fungal organisms; however, the diagnostic value 
of biopsy is highly correlative to the site sampled. 
The detection of calcium oxalate crystals in BAL 
within 24 hours of collection, coupled with trache-
obronchial necrosis raised the clinical suspicion 
for IPA, and lead to early initiation of treatment.
The treatment for proven pulmonary aspergil-
losis is based on intravenous azoles, echinocandins, 
and amphotericin B [5–9]. Invasive forms of pulmo-
nary aspergillosis require intravenous azoles (vorico-
nazole as first-line), which can be deescalated to oral 
regimens with clinical improvement, and treatment 
lasts about 6–12 weeks at which time radiological 
and clinical symptoms are resolved. Frequently, 
parenchymal damages are irreversible [10–13].
According to the European Organization for 
Research and Treatment of Cancer/Mycosis Study 
Group (EORTC/MSG), pulmonary oxalosis is not 
currently considered a part of the standardized 
criteria for the diagnosis of aspergillosis. Chec-
king for the presence of pulmonary oxalosis in 
the BAL sputum during the workup of patients 
suspected of invasive pulmonary disease is of 
high yield potential in early diagnosis. Eradica-
tion of pulmonary aspergillosis syndromes can 
be difficult to achieve with a heavy infectious 
burden and severe immunosuppression, and 
early initiation of treatment is recommended. We 
present this case to emphasize the importance of 
pulmonary oxalosis as an early diagnostic clue 
for Aspergillus tissue invasion prior to results from 
cultures, lab tests, and tissue biopsy, which can 
take longer to yield results.
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